Welcome to our dedicated page for CEL-SCI SEC filings (Ticker: CVM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CEL-SCI Corporation filings document a clinical-stage biotechnology issuer funding the development of Multikine through registered securities offerings and reporting material corporate actions. Registration statements and prospectus-related filings describe common stock issuance capacity, use of proceeds for Multikine development, working capital, risk factors, operating and financial results, and the company's capital structure.
Current reports on Form 8-K record placement agency agreements, closed equity offerings, and amendments to the company's Shareholder Rights Agreement, including modifications to security-holder rights. The filing record also provides formal disclosure around governance, material agreements, and financing terms tied to CEL-SCI's cancer immunotherapy development business.
CEL-SCI Corp (CVM) – Form 4 insider transaction
Director Robert E. Watson bought 2,919 restricted shares of CEL-SCI on 25-Jul-2025 at $6.85 (prior day’s close), a cash outlay of roughly $20k. Following the purchase, Watson’s direct holdings increased to 3,733 shares. No derivative securities were involved and the filing shows the transaction was made directly with the company, suggesting an equity-based compensation or voluntary open-market style purchase rather than option exercise or planned sale. The filing does not reference any concurrent sales, options, or changes in indirect ownership.
The transaction is modest relative to CEL-SCI’s market capitalization and daily trading volume, but insider buying—especially by a board member—can signal personal confidence in the company’s prospects and may be viewed positively by investors monitoring governance alignment.
Cel-Sci Corp. (CVM) Form 4 filing discloses that Chief Executive Officer and Director Geert R. Kersten purchased 2,292 shares of common stock on 06/30/2025 at a price of $2.29 per share. Following the transaction, Kersten directly holds 43,638 shares. No derivative security activity was reported. The filing was signed on 07/01/2025 and represents a single-person submission under Section 16 reporting requirements.